Development of a safe and immunogenic anti-chlamydia vaccine for the koala. Many koala populations are under threat of extinction from chlamydial disease.The project will develop a chlamydial vaccine and conduct trials in several wild koala populations for safety and effectiveness.
The development and evaluation of a new therapy for the prevention and treatment of bacterial infections in hospitals. The technology used in this project will enable products to be developed from the Australian dairy industry which may safely provide protection and treatment for diarrhoea acquired in hospitals for which there are few effective options. The product will be cost effective and can be used as a public health tool to control outbreaks in those most susceptible to severe disease.
Functional characterisation of poly-histidine triad proteins. This project aims to understand the role and function of a novel family of surface proteins produced by Streptococci. These so-called polyhistidine triad proteins are known to contribute to capacity to cause disease in animals and humans, but we need to know how they work, as they may be excellent targets for novel drugs or vaccines.
Novel perspectives on the function of AB5 toxin B subunits in pathogenic bacterial. AB5 toxins are produced by bacteria that cause important diseases in humans and livestock. This project tests the hypothesis that the components of the toxins responsible for binding to host cells and tissues also directly contribute to cellular damage, thereby providing a better understanding of how AB5 toxin-producing bacteria cause disease.
How bacteria cause disease in the urinary tract. This project will investigate the virulence properties of uropathogenic Escherichia coli, the major causative agent of urinary tract infections (UTI) in humans. The results will help to understand how these bacterial pathogens cause disease and will impact strategies aimed at the prevention and treatment of chronic and recurrent UTI.
Plasmid Specialisation Modules, Microbial Husbandry And Microbiome Resilience
Funder
National Health and Medical Research Council
Funding Amount
$645,005.00
Summary
The epidemiology of plasmids is chiefly determined by small genetic modules that control their entry to cells, their stability after entry, and their capacity to exclude other related plasmids. Understanding this is important for understanding transmission of antibiotic resistance. It is also essential for our newly proven approach to remove resistance plasmids from bacteria.
A single vaccine for influenza and pneumonia. Influenza and bacterial pneumonia collaborate to kill millions of people each year. This project aims to develop a single vaccine that will provide long-lasting protection against both influenza and pneumonia.
Crohn’s disease (CD), an inflammatory disorder of the gut, is thought to result from an inappropriate response to an environmental trigger, likely gut bacteria. This project will assess differences in microbial communities and host gene expression of early- and late-stage CD tissues. A greater understanding of the differences in mucosal gene expression induced by specific bacteria may provide insights into the pathophysiology of CD, and could conceivably guide therapeutic choices in the future.
Molecular characterisation of hypervirulence and the infectious cycle in Clostridium difficile. Gut diseases caused by the bacterium Clostridium difficile are a significant animal and public health problem in Australia and many other countries. This project will allow us to understand how this bacterium causes disease, leading to the development of much needed preventative and treatment strategies for animals and human patients.
Host-pathogen interactions: the role of mimicry. The proposed research program, using a combination of structure and functional analysis will provide insight into the mechanism of nucleotide hydrolysis by the enzymes NTPDases. This study will not only improve our fundamental understanding of NTPDase action but could lead to the rational design of antimicrobials.